Member Login
Search

LUGPA 2025 Annual Meeting Enduring CME Program   

     
      Disclaimer:
Participants who previously attended the live LUGPA 2025
CME Program and claimed CME are not eligible to claim CME credit
for the corresponding enduring activity.

NOW AVAILABLE!

Access the course by logging into LUGPALearn with your single sign on.   

 

Grant Support:

This activity was supported by unrestricted grants from Ferring, AstraZeneca, Pfizer, Blue
Earth, Lantheus and Calyxo.

Course Description:

 

Adapted from the live programs presented at the LUGPA 2025 Annual Meeting, this enduring activity provides continuous access to the latest updates, evidence, and innovations shaping contemporary urologic practice. Designed for practicing urologists and advanced practice providers, this comprehensive program offers an in-depth review of rapidly evolving diagnostic tools, surgical techniques, and therapeutic strategies across the major domains of urologic care.

Participants will explore emerging treatments for bladder cancer, procedural advancements in stone disease, cutting-edge applications of PSMA PET imaging, updated guidance for testosterone therapy, and evolving technologies in robotic surgery and radioligand therapy. The program also highlights the expanding role of immunotherapy and next-generation imaging, ensuring clinicians remain equipped to deliver high-quality, evidence-based, patient-centered care.

Learning Objectives:

  1. Evaluate emerging therapies and current standards of care for NMIBC and MIBC.
  2. Compare procedural innovations in stone management, including aspiration-directed lithotripsy and mini-PCNL.
  3. Apply updated guidelines and best practices for testosterone therapy in 2025.
  4. Interpret PSMA PET imaging and utilize advanced PSA biomarkers and genetic testing in prostate cancer care.
  5. Assess novel surgical approaches, including SP and multiport robotic prostatectomy techniques.
  6. Identify infrastructure and readiness requirements for implementing radioligand therapy.
  7. Incorporate advancements in immunotherapy and imaging into clinical decision-making for urologic cancers.

Accreditation and Designation Statement  

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the LUPGA.

PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians. PeerPoint Medical Education Institute designates the live and enduring formats for this educational activity for a maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activities.

The enduring approval period is: December 18, 2025 – December 18, 2028

Course completion data is submitted to PeerPoint on the first of each month. Once your information has been added, and you are officially eligible to claim CME credit, you will receive an email from [email protected] with instructions on how to do so. 

LUGPA 2025 CME Program Accreditation Statements (PDF)

Recorded Sessions Include: 

NMIBC – Navigating the Options and Future Directions

Speaker: Piyush Agarwal, MD, University of Chicago

MIBC – What You Should Be Doing Today and What We Will Be Doing Tomorrow

Speaker: Joshua Meeks, MD, PhD, Northwestern University

Bladder Cancer Panel Discussion

Moderator: Tom Jayram, MD, Urology Associates of Nashville

Panelists:

• Piyush Agarwal, MD – University of Chicago

• Joshua Meeks, MD, PhD – Northwestern Medical Group

Recent Updates in Immunotherapy in Bladder Cancer

Speaker: Suzanne Merrill, MD, Colorado Urology

Steerable Ureteroscopic Renal Stone Evacuation (SURE)

Speaker: Matt Love, MD, The Urology Group

Aspiration Directed Lithotripsy vs Mini PCNL Debate

Judge: David Ellis, MD, MidLantic Urology

Debaters:

• Julio G. Davalos, MD, United Urology Group

• Matt Love, MD, The Urology Group

Testosterone Controversies: Lessons Learned from TRAVERSE 2025

Speaker: Martin Miner, MD, Brown University

How to Read a PSMA PET Scan

Speaker: Steven Rowe, MD, PhD, UNC School of Medicine

SP Radical Prostatectomy

Speaker: Ryan Nelson, DO, Michigan Institute of Urology

Genetic Testing in Prostate Cancer

Speaker: Pedro Barata, MD, University Hospital

Robotic Multiport Radical Prostatectomy

Speaker: Ronney Abaza, MD, Central Ohio Urology Group

Adjuvant PSA Biomarkers Panel Discussion

Moderator: David Albala, MD, Associated Medical Professionals of NY, PLLC

Panelists:

• Benjamin Lowentritt, MD, FACS, Chesapeake Urology

• David Morris, MD, Urology Associates of Nashville

• Jonathan Henderson, MD, Arkansas Urology

Operationalizing Radioligand Therapy – What Is Going to Be Required for the Future?

Speaker: Jeffery Spier, MD, Rio Grande Urology

Prostate MRI 101

Speaker: Aytekin Oto, MD, The University of Chicago